X
[{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences and Blumentech S.L. Announce the Acquisition of a Patent Portfolio Covering the Groundbreaking Discoveries of Prominent Psychedelics Researcher Dr. Jordi Riba","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences Announces Licensing Deal with Sanofi for Two Late-Stage CNS Pipeline Assets ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terran Biosciences Announces Publication Of PCT Patent Applications Covering Orally Active Forms Of DMT and 5-MeO-DMT And Long-Acting MDMA","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences Announces Exclusive Licensing Deal with Pierre Fabre for Idazoxan; Terran Completes Key Development Milestones","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terran Announces Develop of TerXT, Xanomeline &Trospium Prodrugs for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"N\/A","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"N\/A"}]
Find Clinical Drug Pipeline Developments & Deals by Terran Biosciences
Filters
Companies By Therapeutic Area
Details:
TerXT, is a small molecule combination of novel prodrugs of xanomeline and trospium designed to enable fixed-dose combinations for once-daily oral administration for the treatment for schizophrenia.
Lead Product(s):
Xanomeline Prodrug,Trospium Prodrug
Therapeutic Area: Psychiatry/Psychology
Product Name: TerXT
Highest Development Status: N/A
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 20, 2024
Details:
Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.
Lead Product(s):
Idazoxan
Therapeutic Area: Psychiatry/Psychology
Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Recipient:
Pierre Fabre
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
June 02, 2023
Details:
N,N-dimethyltryptamine is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Lead Product(s):
Dimethyltryptamine
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 03, 2023
Details:
Terran plans to quickly advance the development of the lead SAR442168 and other assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.
Lead Product(s):
Tolebrutinib
Therapeutic Area: Neurology
Product Name: SAR442168
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Sanofi
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
April 21, 2022
Details:
Blumentech's patents further complement Terran's rapidly growing IP portfolio of over 150 patent applications in the psychedelic space, which includes patents on Terran's orally-active DMT compound, a product of Terran's robust medicinal chemistry drug discovery program.
Lead Product(s):
Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Small molecule
Recipient:
Blumentech S.L.
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
April 13, 2022